Grove Bank & Trust Sells 755 Shares of AstraZeneca PLC (NASDAQ:AZN)

Grove Bank & Trust lessened its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 6.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 10,644 shares of the company’s stock after selling 755 shares during the quarter. Grove Bank & Trust’s holdings in AstraZeneca were worth $697,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of the company. McClarren Financial Advisors Inc. boosted its holdings in AstraZeneca by 320.8% during the third quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock valued at $25,000 after purchasing an additional 247 shares in the last quarter. Capital Performance Advisors LLP acquired a new stake in AstraZeneca in the 3rd quarter valued at $28,000. Groupama Asset Managment grew its position in AstraZeneca by 22.9% in the third quarter. Groupama Asset Managment now owns 543,398 shares of the company’s stock valued at $42,000 after acquiring an additional 101,225 shares during the period. Ashton Thomas Securities LLC acquired a new position in AstraZeneca during the third quarter worth $45,000. Finally, Versant Capital Management Inc lifted its holdings in shares of AstraZeneca by 2,618.5% during the fourth quarter. Versant Capital Management Inc now owns 734 shares of the company’s stock valued at $48,000 after acquiring an additional 707 shares during the period. 20.35% of the stock is currently owned by institutional investors.

AstraZeneca Stock Performance

AZN stock opened at $66.60 on Monday. The company has a 50 day moving average price of $66.11 and a 200 day moving average price of $74.48. AstraZeneca PLC has a fifty-two week low of $60.47 and a fifty-two week high of $87.68. The company has a debt-to-equity ratio of 0.71, a current ratio of 0.93 and a quick ratio of 0.71. The stock has a market capitalization of $206.50 billion, a PE ratio of 31.87, a price-to-earnings-growth ratio of 1.05 and a beta of 0.46.

AstraZeneca (NASDAQ:AZN) last issued its quarterly earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.01 by $0.03. The business had revenue of $13.57 billion for the quarter, compared to analyst estimates of $13.08 billion. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The firm’s revenue for the quarter was up 18.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.87 earnings per share. Analysts forecast that AstraZeneca PLC will post 4.11 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on AZN shares. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. UBS Group upgraded shares of AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday, November 20th. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, AstraZeneca presently has a consensus rating of “Buy” and an average target price of $89.75.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.